Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study
We examined the efficacy of intravenous (IV) ibandronate 1 mg/month in patient subgroups in the phase III MOVER study. Here we present results of analyses on the incidence of fractures in patients with prevalent vertebral fractures (1 or ≥2, and ≥3) at screening and femoral neck (FN) bone mineral de...
Gespeichert in:
| Veröffentlicht in: | Journal of bone and mineral metabolism 2017, Vol.35 (1), p.58-64 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 64 |
|---|---|
| container_issue | 1 |
| container_start_page | 58 |
| container_title | Journal of bone and mineral metabolism |
| container_volume | 35 |
| creator | Ito, Masako Tobinai, Masato Yoshida, Seitaro Hashimoto, Junko Nakamura, Toshitaka |
| description | We examined the efficacy of intravenous (IV) ibandronate 1 mg/month in patient subgroups in the phase III MOVER study. Here we present results of analyses on the incidence of fractures in patients with prevalent vertebral fractures (1 or ≥2, and ≥3) at screening and femoral neck (FN) bone mineral density (BMD)
T
scores ≥−2.5 or |
| doi_str_mv | 10.1007/s00774-015-0723-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1877846523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826638180</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-a0721f49591c174dc8b937a3656cf620678cd22e7fecf5e7b98c61f113bcf9dc3</originalsourceid><addsrcrecordid>eNqNkd9uFCEUxomxsWv1AbwxJN54gwVmBoZL02z9kzZNjHo7YZhDh3UWRmBq9318UFm3VmNi4g0kh993Duf7EHrG6CtGqTxN5ZA1oawhVPKK3D5AK1ZXDWkErR-iFVWsJq2U6hg9TmlDKZONZI_QMReC1Y2SK_R9bS2YjIPF2-DzOO2w8znqG_BhSdj12g8xeJ2h1DeFdMEnHDy-gZihj3rCIWIfPPldsFGbvETA0aUvRYbf61l7SIBnnR34nPA3l0c8uuuR_GRCyhDmEENyaS_II-DLq8_rDzjlZdg9QUdWTwme3t0n6NP5-uPZW3Jx9ebd2esLYmquMtHFBGZr1ShmmKwH0_aqkroSjTBWcCpkawbOQZaNbQOyV60RzDJW9caqwVQn6OWh7xzD1wVS7rYuGZim8vviRseKl20tGl79B1o8rlrW0oK--AvdhCX6skihhFS8bSteKHagTHEhRbDdHN1Wx13HaLdPuzuk3ZW0u33a3W3RPL_rvPRbGO4Vv-ItAD8AqTz5a4h_jP5n1x_I4ri7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1867928832</pqid></control><display><type>article</type><title>Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Ito, Masako ; Tobinai, Masato ; Yoshida, Seitaro ; Hashimoto, Junko ; Nakamura, Toshitaka</creator><creatorcontrib>Ito, Masako ; Tobinai, Masato ; Yoshida, Seitaro ; Hashimoto, Junko ; Nakamura, Toshitaka</creatorcontrib><description>We examined the efficacy of intravenous (IV) ibandronate 1 mg/month in patient subgroups in the phase III MOVER study. Here we present results of analyses on the incidence of fractures in patients with prevalent vertebral fractures (1 or ≥2, and ≥3) at screening and femoral neck (FN) bone mineral density (BMD)
T
scores ≥−2.5 or <−2.5, and <−3.0 at baseline. The per-protocol set comprised 1134 patients (ibandronate 0.5 mg/month
n
= 376; ibandronate 1 mg/month
n
= 382; risedronate oral 2.5 mg/day
n
= 376). The incidence of vertebral fractures in patients with 1 or ≥2 prevalent vertebral fractures was 11.2 and 20.4 %, respectively, with ibandronate 1 mg/month, and 12.6 and 22.1 %, respectively, with risedronate. In patients with FN BMD
T
scores ≥−2.5 or <−2.5, the vertebral fracture incidence was 13.7 and 16.4 %, respectively, with ibandronate 1 mg/month, and 17.3 and 19.1 %, respectively, with risedronate. The incidence of non-vertebral fractures in patients with ≥2 prevalent vertebral fractures or FN BMD
T
score <−2.5 was 7.6 and 7.6 %, respectively, with ibandronate 1 mg/month, and 9.5 and 9.4 %, respectively, with risedronate. Fracture incidence was consistently lower, but not significant, with ibandronate 1 mg/month than with risedronate in patients with ≥2 prevalent vertebral fractures and FN BMD
T
score <−2.5. The efficacy of the fracture reduction of monthly IV ibandronate appears consistent and seemingly independent of the number of prevalent vertebral fractures or baseline BMD values.</description><identifier>ISSN: 0914-8779</identifier><identifier>EISSN: 1435-5604</identifier><identifier>DOI: 10.1007/s00774-015-0723-x</identifier><identifier>PMID: 26614597</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Aged ; Aged, 80 and over ; Asian Continental Ancestry Group ; Bone Density - drug effects ; Diphosphonates - administration & dosage ; Female ; Femoral Neck Fractures - epidemiology ; Femoral Neck Fractures - etiology ; Femoral Neck Fractures - metabolism ; Femoral Neck Fractures - prevention & control ; Femur Neck - metabolism ; Humans ; Japan - epidemiology ; Male ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Middle Aged ; Original Article ; Orthopedics ; Osteoporosis - complications ; Osteoporosis - drug therapy ; Osteoporosis - epidemiology ; Osteoporosis - metabolism ; Risedronate Sodium - administration & dosage ; Spinal Fractures - epidemiology ; Spinal Fractures - etiology ; Spinal Fractures - metabolism ; Spinal Fractures - prevention & control ; Spine - metabolism</subject><ispartof>Journal of bone and mineral metabolism, 2017, Vol.35 (1), p.58-64</ispartof><rights>The Japanese Society for Bone and Mineral Research and Springer Japan 2015</rights><rights>Journal of Bone and Mineral Metabolism is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-a0721f49591c174dc8b937a3656cf620678cd22e7fecf5e7b98c61f113bcf9dc3</citedby><cites>FETCH-LOGICAL-c429t-a0721f49591c174dc8b937a3656cf620678cd22e7fecf5e7b98c61f113bcf9dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00774-015-0723-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00774-015-0723-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26614597$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ito, Masako</creatorcontrib><creatorcontrib>Tobinai, Masato</creatorcontrib><creatorcontrib>Yoshida, Seitaro</creatorcontrib><creatorcontrib>Hashimoto, Junko</creatorcontrib><creatorcontrib>Nakamura, Toshitaka</creatorcontrib><title>Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study</title><title>Journal of bone and mineral metabolism</title><addtitle>J Bone Miner Metab</addtitle><addtitle>J Bone Miner Metab</addtitle><description>We examined the efficacy of intravenous (IV) ibandronate 1 mg/month in patient subgroups in the phase III MOVER study. Here we present results of analyses on the incidence of fractures in patients with prevalent vertebral fractures (1 or ≥2, and ≥3) at screening and femoral neck (FN) bone mineral density (BMD)
T
scores ≥−2.5 or <−2.5, and <−3.0 at baseline. The per-protocol set comprised 1134 patients (ibandronate 0.5 mg/month
n
= 376; ibandronate 1 mg/month
n
= 382; risedronate oral 2.5 mg/day
n
= 376). The incidence of vertebral fractures in patients with 1 or ≥2 prevalent vertebral fractures was 11.2 and 20.4 %, respectively, with ibandronate 1 mg/month, and 12.6 and 22.1 %, respectively, with risedronate. In patients with FN BMD
T
scores ≥−2.5 or <−2.5, the vertebral fracture incidence was 13.7 and 16.4 %, respectively, with ibandronate 1 mg/month, and 17.3 and 19.1 %, respectively, with risedronate. The incidence of non-vertebral fractures in patients with ≥2 prevalent vertebral fractures or FN BMD
T
score <−2.5 was 7.6 and 7.6 %, respectively, with ibandronate 1 mg/month, and 9.5 and 9.4 %, respectively, with risedronate. Fracture incidence was consistently lower, but not significant, with ibandronate 1 mg/month than with risedronate in patients with ≥2 prevalent vertebral fractures and FN BMD
T
score <−2.5. The efficacy of the fracture reduction of monthly IV ibandronate appears consistent and seemingly independent of the number of prevalent vertebral fractures or baseline BMD values.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Asian Continental Ancestry Group</subject><subject>Bone Density - drug effects</subject><subject>Diphosphonates - administration & dosage</subject><subject>Female</subject><subject>Femoral Neck Fractures - epidemiology</subject><subject>Femoral Neck Fractures - etiology</subject><subject>Femoral Neck Fractures - metabolism</subject><subject>Femoral Neck Fractures - prevention & control</subject><subject>Femur Neck - metabolism</subject><subject>Humans</subject><subject>Japan - epidemiology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Osteoporosis - complications</subject><subject>Osteoporosis - drug therapy</subject><subject>Osteoporosis - epidemiology</subject><subject>Osteoporosis - metabolism</subject><subject>Risedronate Sodium - administration & dosage</subject><subject>Spinal Fractures - epidemiology</subject><subject>Spinal Fractures - etiology</subject><subject>Spinal Fractures - metabolism</subject><subject>Spinal Fractures - prevention & control</subject><subject>Spine - metabolism</subject><issn>0914-8779</issn><issn>1435-5604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkd9uFCEUxomxsWv1AbwxJN54gwVmBoZL02z9kzZNjHo7YZhDh3UWRmBq9318UFm3VmNi4g0kh993Duf7EHrG6CtGqTxN5ZA1oawhVPKK3D5AK1ZXDWkErR-iFVWsJq2U6hg9TmlDKZONZI_QMReC1Y2SK_R9bS2YjIPF2-DzOO2w8znqG_BhSdj12g8xeJ2h1DeFdMEnHDy-gZihj3rCIWIfPPldsFGbvETA0aUvRYbf61l7SIBnnR34nPA3l0c8uuuR_GRCyhDmEENyaS_II-DLq8_rDzjlZdg9QUdWTwme3t0n6NP5-uPZW3Jx9ebd2esLYmquMtHFBGZr1ShmmKwH0_aqkroSjTBWcCpkawbOQZaNbQOyV60RzDJW9caqwVQn6OWh7xzD1wVS7rYuGZim8vviRseKl20tGl79B1o8rlrW0oK--AvdhCX6skihhFS8bSteKHagTHEhRbDdHN1Wx13HaLdPuzuk3ZW0u33a3W3RPL_rvPRbGO4Vv-ItAD8AqTz5a4h_jP5n1x_I4ri7</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Ito, Masako</creator><creator>Tobinai, Masato</creator><creator>Yoshida, Seitaro</creator><creator>Hashimoto, Junko</creator><creator>Nakamura, Toshitaka</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>2017</creationdate><title>Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study</title><author>Ito, Masako ; Tobinai, Masato ; Yoshida, Seitaro ; Hashimoto, Junko ; Nakamura, Toshitaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-a0721f49591c174dc8b937a3656cf620678cd22e7fecf5e7b98c61f113bcf9dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Asian Continental Ancestry Group</topic><topic>Bone Density - drug effects</topic><topic>Diphosphonates - administration & dosage</topic><topic>Female</topic><topic>Femoral Neck Fractures - epidemiology</topic><topic>Femoral Neck Fractures - etiology</topic><topic>Femoral Neck Fractures - metabolism</topic><topic>Femoral Neck Fractures - prevention & control</topic><topic>Femur Neck - metabolism</topic><topic>Humans</topic><topic>Japan - epidemiology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Osteoporosis - complications</topic><topic>Osteoporosis - drug therapy</topic><topic>Osteoporosis - epidemiology</topic><topic>Osteoporosis - metabolism</topic><topic>Risedronate Sodium - administration & dosage</topic><topic>Spinal Fractures - epidemiology</topic><topic>Spinal Fractures - etiology</topic><topic>Spinal Fractures - metabolism</topic><topic>Spinal Fractures - prevention & control</topic><topic>Spine - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ito, Masako</creatorcontrib><creatorcontrib>Tobinai, Masato</creatorcontrib><creatorcontrib>Yoshida, Seitaro</creatorcontrib><creatorcontrib>Hashimoto, Junko</creatorcontrib><creatorcontrib>Nakamura, Toshitaka</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of bone and mineral metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ito, Masako</au><au>Tobinai, Masato</au><au>Yoshida, Seitaro</au><au>Hashimoto, Junko</au><au>Nakamura, Toshitaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study</atitle><jtitle>Journal of bone and mineral metabolism</jtitle><stitle>J Bone Miner Metab</stitle><addtitle>J Bone Miner Metab</addtitle><date>2017</date><risdate>2017</risdate><volume>35</volume><issue>1</issue><spage>58</spage><epage>64</epage><pages>58-64</pages><issn>0914-8779</issn><eissn>1435-5604</eissn><abstract>We examined the efficacy of intravenous (IV) ibandronate 1 mg/month in patient subgroups in the phase III MOVER study. Here we present results of analyses on the incidence of fractures in patients with prevalent vertebral fractures (1 or ≥2, and ≥3) at screening and femoral neck (FN) bone mineral density (BMD)
T
scores ≥−2.5 or <−2.5, and <−3.0 at baseline. The per-protocol set comprised 1134 patients (ibandronate 0.5 mg/month
n
= 376; ibandronate 1 mg/month
n
= 382; risedronate oral 2.5 mg/day
n
= 376). The incidence of vertebral fractures in patients with 1 or ≥2 prevalent vertebral fractures was 11.2 and 20.4 %, respectively, with ibandronate 1 mg/month, and 12.6 and 22.1 %, respectively, with risedronate. In patients with FN BMD
T
scores ≥−2.5 or <−2.5, the vertebral fracture incidence was 13.7 and 16.4 %, respectively, with ibandronate 1 mg/month, and 17.3 and 19.1 %, respectively, with risedronate. The incidence of non-vertebral fractures in patients with ≥2 prevalent vertebral fractures or FN BMD
T
score <−2.5 was 7.6 and 7.6 %, respectively, with ibandronate 1 mg/month, and 9.5 and 9.4 %, respectively, with risedronate. Fracture incidence was consistently lower, but not significant, with ibandronate 1 mg/month than with risedronate in patients with ≥2 prevalent vertebral fractures and FN BMD
T
score <−2.5. The efficacy of the fracture reduction of monthly IV ibandronate appears consistent and seemingly independent of the number of prevalent vertebral fractures or baseline BMD values.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>26614597</pmid><doi>10.1007/s00774-015-0723-x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0914-8779 |
| ispartof | Journal of bone and mineral metabolism, 2017, Vol.35 (1), p.58-64 |
| issn | 0914-8779 1435-5604 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1877846523 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Aged, 80 and over Asian Continental Ancestry Group Bone Density - drug effects Diphosphonates - administration & dosage Female Femoral Neck Fractures - epidemiology Femoral Neck Fractures - etiology Femoral Neck Fractures - metabolism Femoral Neck Fractures - prevention & control Femur Neck - metabolism Humans Japan - epidemiology Male Medicine Medicine & Public Health Metabolic Diseases Middle Aged Original Article Orthopedics Osteoporosis - complications Osteoporosis - drug therapy Osteoporosis - epidemiology Osteoporosis - metabolism Risedronate Sodium - administration & dosage Spinal Fractures - epidemiology Spinal Fractures - etiology Spinal Fractures - metabolism Spinal Fractures - prevention & control Spine - metabolism |
| title | Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A27%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20monthly%20intravenous%20ibandronate%20injections%20on%20vertebral%20or%20non-vertebral%20fracture%20risk%20in%20Japanese%20patients%20with%20high-risk%20osteoporosis%20in%20the%20MOVER%20study&rft.jtitle=Journal%20of%20bone%20and%20mineral%20metabolism&rft.au=Ito,%20Masako&rft.date=2017&rft.volume=35&rft.issue=1&rft.spage=58&rft.epage=64&rft.pages=58-64&rft.issn=0914-8779&rft.eissn=1435-5604&rft_id=info:doi/10.1007/s00774-015-0723-x&rft_dat=%3Cproquest_cross%3E1826638180%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1867928832&rft_id=info:pmid/26614597&rfr_iscdi=true |